Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

ICER panel split on value of CAR Ts

March 2, 2018 11:42 PM UTC

The Institute for Clinical and Economic Review's California Technology Assessment Forum voted that the value of Kymriah tisagenlecleucel was intermediate, while the panel was mixed on whether the value of Yescarta axicabtagene ciloleucel was intermediate or low.

Seven members voted that the value of Kymriah from Novartis AG (NYSE:NVS; SIX:NOVN) has an intermediate value compared with clofarabine, while 3 voted it had high value. The remaining vote was for low value...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Gilead Sciences Inc.

Novartis AG

BCIQ Target Profiles

CD19